0001493152-24-020909.txt : 20240521 0001493152-24-020909.hdr.sgml : 20240521 20240521170015 ACCESSION NUMBER: 0001493152-24-020909 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240515 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240521 DATE AS OF CHANGE: 20240521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTRICITY INC. CENTRAL INDEX KEY: 0001630113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 472548273 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40761 FILM NUMBER: 24970382 BUSINESS ADDRESS: STREET 1: 203 REDWOOD PARKWAY STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: (650) 832-1626 MAIL ADDRESS: STREET 1: 203 REDWOOD PARKWAY STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: METASOLUTIONS, INC. DATE OF NAME CHANGE: 20150107 8-K 1 form8-k.htm
false 0001630113 0001630113 2024-05-15 2024-05-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): May 15, 2024

 

BIOTRICITY INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-40761   30-0983531

(State or Other Jurisdiction of

Incorporation or Organization)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

203 Redwood Shores Parkway, Suite 600

Redwood City, California 94065

(Address of Principal Executive Offices)

 

(650) 832-1626

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Class   Trading Symbol (s)   Name of each exchange on which registered
Common Stock, Par Value $0.001   BTCY   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 3.02. Unregistered Sales of Equity Securities.

 

The information contained in Item 8.01 relating to the Private Placement (defined below) is hereby incorporated by reference into this Item 3.02. Based in part upon the representations of the Investor (defined below) in the Purchase Agreement, the offering and sale of the securities was made in reliance on the exemption afforded by Regulation D under the Securities Act of 1933, as amended (the “Securities Act”), and corresponding provisions of state securities or “blue sky” laws. The securities, when initially issued and sold, will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from the registration requirements. The sale of the securities did not involve a public offering and was made without general solicitation or general advertising. The Investor represented that it is an accredited investor, as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and that it was acquiring the securities for investment purposes only and not with a view to any resale, distribution or other disposition of the securities in violation of the U.S. federal securities laws.

 

Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy the securities of the Company.

 

Item 8.01 Other Events.

 

As previously reported, on March 25, 2024, Biotricity Inc. (the “Company”) consummated the first closing (the “First Closing”) pursuant to a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”) for the issuance and sale, in a private placement offering (the “Private Placement”), of 110 shares of the Company’s Series B Convertible Preferred Stock, $0.001 par value (the “Series B Preferred Stock”), at a purchase price of $9,090.91 per share of Series B Convertible Preferred Stock, for gross proceeds of $1,000,000, with an option, at any time prior to the 30th calendar day following the First Closing, for the Company to require the Investor to consummate a second closing (the “Second Closing”) to purchase up to an additional 110 shares of the Company’s Series B Preferred Stock at a purchase price of $9,090.91 per share for gross proceeds of up to $1,000,000. Also as previously reported, on April 30, 2024, the Company consummated a second closing pursuant to the Purchase Agreement (the “Second Closing”) for the issuance and sale of 39 shares of Series B Preferred Stock for gross proceeds of $354,545. On May 15, 2024, pursuant to the Purchase Agreement and a side letter between the Company and the Investor, the Company consummated an additional closing for the issuance and sale of 71 shares of Series B Preferred Stock for gross proceeds of $645,455. A copy of the side letter is filed as Exhibit 10.1 to the Current Report on Form 8-K and is incorporated herein by reference.

 

Pursuant to the Purchase Agreement, the Company also agreed to seek the approval of the Company’s stockholders that may be required upon conversion of the Series B Preferred Stock (the “Stockholder Approval”), if required by the applicable rules and regulations of Nasdaq Capital Market. The Company agreed to hold an annual or special meeting of stockholders for the purpose of obtaining Stockholder Approval as soon as practicable, but in no event later than 75 days following the date on which two conversions of Series B Preferred Stock by the Investor would require approval of the Company’s stockholder, and to hold a meeting every three (3) months thereafter for the purpose of obtaining Stockholder Approval if the proposal is not approved at the first meeting until Stockholder Approval is obtained.

 

As previously reported, the Company also entered into a Registration Rights Agreement, dated March 25, 2024, with the Investor (the “Registration Rights Agreement”), pursuant to which the Company agreed, among other things, to: (i) within forty-five (45) days after the date of the Purchase Agreement, with respect to the shares issuable upon conversion of the Series B Preferred Stock (the “Conversion Shares”) that may, from time to time, be issued or become issuable to the Investor with respect to the shares Series B Preferred Stock under the Purchase Agreement on the First Closing, and (ii) within ten (10) days after the Second Closing Date with respect to the Conversion Shares that may, from time to time, be issued or become issuable to the Investor with respect to the shares of Series B Preferred Stock under the Purchase Agreement on the Second Closing, file with the SEC an initial registration statement (the “Registration Statement”) covering the maximum number of Registrable Securities (as such term is defined in the Registration Rights Agreement), to have the Registration Statement declared effective within 30 calendar days of filing of the Registration Statement (or 90 calendar days if the Registration Statement is subject to a full review). In the event of the failure to comply with deadlines to file the Registration Statement or to have such Registration Statement declared effective, the Company is obligated in each event to issue to the Investor 100,000 shares of common stock.

 

 
 

 

On May 9, 2024, the Company filed a registration statement on Form S-3 (the “Form S-3”) registering for resale by the Investor up to 1,419,047 shares of common stock issuable upon conversion of the 149 shares of Series B Preferred Stock issued and sold to the Investor at the First Closing and Second Closing. On May 15, 2024, the Company filed an amendment to the Form S-3 to increase the number of shares of common stock registered for resale by the Investor to 2,095,238 shares issuable upon conversion of the full 220 shares of Series B Preferred Stock that were issued and sold to the Investor pursuant to the Purchase Agreement. At the time of the filing of this Current Report on Form 8-K, the Form S-3 has not been declared effective by the SEC.

 

The foregoing summaries of the Side Letter, Purchase Agreement and the Registration Rights Agreement do not purport to be complete and are qualified in their entirety by reference to the Purchase Agreement and the Registration Rights Agreement, which are filed as exhibits to this Current Report on Form 8-K or incorporated herein by reference as Exhibits 10.1, 10.2 and 10.3 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
10.1   Side letter, dated May 15, 2024
10.2   Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on March 26, 2024)
10.3   Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on May 3, 2024)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: May 21, 2024

 

  BIOTRICITY INC.
     
  By: /s/ Waqaas Al-Siddiq
    Waqaas Al-Siddiq
    Chief Executive Officer

 

 

 

 

 EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

Biotricity Inc.

Amended Side Letter

May 15, 2024

 

May 15, 2024

 

Ionic Ventures, LLC

3053 Fillmore St., Suite 256

San Francisco, CA 94123

 

Re: Modification of the Securities Purchase Agreement by Amended Letter Agreement

 

Dear Sirs:

 

Reference is made to that certain (a) (i) Securities Purchase Agreement (as modified from time to time, the “Securities Purchase Agreement”), dated as of March 25, 2024, between the Company and the purchaser identified therein (the “Investor”) regarding that certain March 2024 Series B Preferred financing, and (ii) the other transaction documents, as modified from time to time, referred to collectively, as the “Securities Purchase Agreement Transaction Documents”), (ii) the other transaction documents, as modified from time to time, referred to collectively, as the “Transaction Documents” and together with the Securities Purchase Agreement Transaction Documents referred to collectively as the “Transaction Documents”) and (iii) that certain Letter Agreement between the Company and the Investor dated May 13, 2024 (the “Letter Agreement”). Capitalized terms used but not defined herein shall have the meanings given to them in the Securities Purchase Agreement.

 

This amended and restated letter agreement (this “Amended Letter Agreement”) amends the Letter Agreement and reconfirms our recent discussions about, among other matters, following modifications to the Securities Purchase Agreement.

 

  (1) This Amended Letter Agreement shall be deemed to be a Securities Purchase Agreement Transaction Document.
     
  (2) The Investor hereby provides an express waiver of the terms in Section 1(b) of the Securities Purchase Agreement whereby the Company shall have the right to require the Purchasers to consummate an additional closing, a third closing (the “Third Closing Date”), even though such additional closing is outside the 30th calendar day following the First Closing Date.
     
  (3) The Purchasers shall purchase $645,455 of the remaining amount committed as part of the March 2024 Series B Preferred financing under the Third Closing Date.
     
  (4) The defined term “Closing Date” shall also include the Third Closing Date, in addition to the First Closing Date and the Second Closing Date.
     
  (5) The Company will deliver the Purchasers a certificate evidencing good standing of the Company in California, where the Company is qualified to do business, within ten (10) Business Days of the date first written above. If the Company fails to deliver the certificate of good standing of the Company in California, as stated above, it will constitute a breach of the Securities Purchase Agreement by the Company.
     
  (6) All closing conditions required in the Securities Purchase Agreement shall apply to the Third Closing Date.

 

The Company hereby reaffirms all such obligations and liabilities and agrees that such obligations and liabilities shall remain in full force and effect.

 

 1
 

 

Biotricity Inc.

Amended Side Letter

May 15, 2024

 

This Amended Letter Agreement is a Securities Purchase Agreement Transaction Document and is limited as written. As of the date first written above, each reference in the Securities Purchase Agreement or any other applicable Securities Purchase Agreement Transaction Document to “this Agreement,” “hereunder,” “hereof,” “herein,” or words of like import, and each reference in the other Securities Purchase Agreement Transaction Documents to such Securities Purchase Agreement or other Purchase Agreement Transaction Documents (including, without limitation, by means of words like “thereunder,” “thereof” and words of like import), shall refer to the Securities Purchase Agreement as modified thereby, and this Amended Letter Agreement and the Securities Purchase Agreement shall be read together and construed as a single agreement. The execution, delivery and effectiveness of this Amended Letter Agreement shall not, except as expressly provided herein, (A) waive or modify any right, power or remedy under, or any other provision of, any Transaction Document or (B) commit or otherwise obligate Investor to enter into or consider entering into any other amendment, waiver or modification of any Transaction Document.

 

All communications and notices hereunder shall be given as provided in the Securities Purchase Agreement Transaction Documents. This Amended Letter Agreement (a) shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York, (b) is for the exclusive benefit of the parties hereto and beneficiaries of the Securities Purchase Agreement and, together with the other Transaction Documents, constitutes the entire agreement of such parties, superseding all prior agreements among them, with respect to the subject matter hereof, (c) may be modified, waived or assigned only in writing and only to the extent such modification, waiver or assignment would be permitted under the Transaction Documents (and any attempt to assign this Amended Letter Agreement without such writing shall be null and void), (d) is a negotiated document, entered into freely among the parties upon advice of their own counsel, and it should not be construed against any of its drafters and (e) shall survive the satisfaction or discharge of the amounts owing under the Transaction Documents. The fact that any term or provision of this Amended Letter Agreement is held invalid, illegal or unenforceable as to any person in any situation in any jurisdiction shall not affect the validity, enforceability or legality of the remaining terms or provisions hereof or the validity, enforceability or legality of such offending term or provision in any other situation or jurisdiction or as applied to any person.

 

Kindly confirm your agreement with the above by signing in the space indicated below and by PDFing a partially executed copy of this letter to the undersigned, and which may be executed in identical counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement.

 

  Very truly yours,
     
  BIOTRICITY INC.
     
  By: /s/ Waqaas Al-Siddiq
  Name: Waqaas Al-Siddiq
  Title: CEO

 

AGREED AND ACCEPTED:  
     
Ionic Ventures, LLC  
     
By: /s/ Brendan O’Neil  
Name: Brendan O’Neil  
Title: Authorized Signatory  

 

 2

 

 EX-101.SCH 3 btcy-20240515.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 btcy-20240515_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 btcy-20240515_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 15, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 15, 2024
Entity File Number 001-40761
Entity Registrant Name BIOTRICITY INC.
Entity Central Index Key 0001630113
Entity Tax Identification Number 30-0983531
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 203 Redwood Shores Parkway
Entity Address, Address Line Two Suite 600
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code (650)
Local Phone Number 832-1626
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.001
Trading Symbol BTCY
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://biotricity.com/role/Cover Cover Cover 1 false false All Reports Book All Reports btcy-20240515.xsd btcy-20240515_lab.xml btcy-20240515_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "BTCY", "nsuri": "http://biotricity.com/20240515", "dts": { "schema": { "local": [ "btcy-20240515.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "btcy-20240515_lab.xml" ] }, "presentationLink": { "local": [ "btcy-20240515_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://biotricity.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-24-020909-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-020909-xbrl.zip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end XML 17 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001630113 2024-05-15 2024-05-15 iso4217:USD shares iso4217:USD shares false 0001630113 8-K 2024-05-15 BIOTRICITY INC. NV 001-40761 30-0983531 203 Redwood Shores Parkway Suite 600 Redwood City CA 94065 (650) 832-1626 false false false false Common Stock, Par Value $0.001 BTCY NASDAQ false